MerckMRK
MRK
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 1,498 | Existing positions reduced: 1,391
7% more call options, than puts
Call options by funds: $1.98B | Put options by funds: $1.85B
8% less first-time investments, than exits
New positions opened: 146 | Existing positions closed: 159
2% less funds holding
Funds holding: 3,480 [Q2] → 3,420 (-60) [Q3]
3.03% less ownership
Funds ownership: 79.82% [Q2] → 76.78% (-3.03%) [Q3]
12% less capital invested
Capital invested by funds: $251B [Q2] → $221B (-$29.8B) [Q3]
42% less funds holding in top 10
Funds holding in top 10: 190 [Q2] → 111 (-79) [Q3]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$105
10%
upside
Avg. target
$116
21%
upside
High target
$130
36%
upside
8 analyst ratings
4 positive
50%
4 neutral
50%
0 negative
0%
Morgan Stanley Terence Flynn 38% 1-year accuracy 6 / 16 met price target | 18%upside $113 | Equal-Weight Maintained | 21 Jan 2025 |
Leerink Partners Daina Graybosch 0% 1-year accuracy 0 / 2 met price target | 25%upside $119 | Outperform Maintained | 13 Jan 2025 |
UBS Colin Bristow 12% 1-year accuracy 2 / 17 met price target | 26%upside $120 | Buy Maintained | 8 Jan 2025 |
Truist Securities Robyn Karnauskas 11% 1-year accuracy 3 / 27 met price target | 15%upside $110 | Hold Downgraded | 8 Jan 2025 |
BMO Capital Evan David Seigerman 10% 1-year accuracy 2 / 20 met price target | 10%upside $105 | Market Perform Downgraded | 20 Dec 2024 |
Financial journalist opinion
Based on 42 articles about MRK published over the past 30 days
Negative
The Motley Fool
1 day ago
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in the economy and the markets.
Negative
Reuters
2 days ago
Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve overall survival in patients with a type of esophageal cancer in a late-stage trial, the companies said on Friday.
Neutral
Business Wire
2 days ago
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial.
Positive
24/7 Wall Street
3 days ago
4 Mega-Cap High-Yield Dividend Giants Look Like Huge 2025 Winners
Investors love dividend stocks, especially the high-yield mega-cap variety, because they offer a significant income stream and have massive total return potential.
Neutral
Reuters
4 days ago
Kennedy would keep legal fees from Merck cases if confirmed
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President Donald Trump's secretary of the U.S. Department of Health and Human Services, according to a federal ethics disclosure made public on Wednesday.
Negative
Zacks Investment Research
5 days ago
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Merck (MRK) closed at $96.24, marking a -1.72% move from the previous day.
Neutral
The Motley Fool
5 days ago
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average (^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 (^GSPC 1.00%) and 28.6% for the Nasdaq Composite.
Positive
Seeking Alpha
6 days ago
Merck: 3x Pipeline And Undervaluation Make It A Buy
Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance with 7% YoY revenue growth, driven by Keytruda and GARDASIL expansions, supports Merck's solid financial health. Merck's 3.3% dividend yield, low net debt-to-EBITDA ratio, and promising late-stage assets enhance its appeal for value and income-oriented investors.
Positive
Seeking Alpha
6 days ago
High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Merck's robust Phase 3 pipeline, strong financials, and sustainable dividend make it a compelling investment despite risks like Medicare negotiations and patent expirations. Merck also appears to have good potential for future growth.
Neutral
Reuters
1 week ago
Exclusive: Kennedy played key role in vaccine case against Merck
Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los Angeles court next week, according to two attorneys close to the case and court filings.
Charts implemented using Lightweight Charts™